MGC Pharmaceuticals - December 2023 Quarter Activity Report
31/01/2024 07:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240131:nRSe5047Ba&default-theme=true
RNS Number : 5047B MGC Pharmaceuticals Limited 31 January 2024
MGC Pharmaceuticals Ltd.
December 2023 Quarter Activity Report and
Cash Flow Statement
31 January 2024
ASX, LSE: MXC
Key Highlights:
· MGC completed a comprehensive corporate restructuring, completing
a 1,000:1 consolidation and conditionally raising a total of US$7.9 million
and US$0.5 million, totalling US$8.4 million over the quarter
· MGC was granted FDA approval in Saudi Arabia for its proprietary
product ArtemiC(TM)
· CMC Markets UK PLC (CMC) were appointed as the Company's joint UK
broker with immediate effect on 1 December 2023
MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) a European based
pharmaceutical company specialising in the production and development of plant
derived medicines, is pleased to provide its Quarterly Activity Report for the
three months ending 31(st) December 2023.
Roby Zomer, Managing Director and CEO of MGC Pharma, commented: "We are
delighted to share positive developments from the business during the December
quarter. MGC successfully concluded a thorough corporate restructuring, which
included a 1,000:1 consolidation. Additionally, the company conditionally
raised a total of US$7.9 million and US$0.5 million, amounting to a total of
US$8.4 million for the quarter. Moreover, we are pleased to announce that the
Company has obtained FDA approval in Saudi Arabia for its proprietary product,
ArtemiC(TM)."
Key Company Activities
ArtemiC™ Receives FDA Approval in Saudi Arabia
On 19 December 2023 MGC announced it had been granted approval for its
proprietary product ArtemiC™ by the Food and Drug Authority in the Kingdom
of Saudi Arabia (Saudi FDA).
Following the success of Phase II clinical trials(( 1 (#_ftn1) )) and
European studies on its effectiveness in assisting with the recovery of
patients from Covid and long-term Covid(( 2 (#_ftn2) )), ArtemiC™ was
approved by the Saudi FDA as an over-the-counter (OTC) dietary supplement.
Capital Blossom, through its joint venture collaboration with its Saudi
partner worked on obtaining the approval of the Saudi FDA for the Company. The
Company is hopeful this will transition into commercial orders for MGC as we
work closely with Capital Blossom Ltd who are specialists in this territory.
Capital Restructuring
During the quarter, the Company completed a comprehensive corporate
restructuring. The restructuring involved a 1,000:1 capital consolidation and
a US$7.9 million fundraising, allowing the Company to proceed with the
execution of its pharmaceutical workplan for 2024. The restructuring now
positions the Company to expand its global footprint and unlock new avenues
for future growth and collaboration.
December Quarter Sales Update
December Quarter Sales Update: MGC Pharma's revenues in the December quarter
were in line with the quarterly average sales.
Corporate and Commercial News
Funding and Cashflow Reporting
During the quarter, the Company conditionally raised US$7.9 million
(~A$12.4million) by way of a placing through the subscription of 31,000,000
new ordinary shares of no-par value (Ordinary Shares) in the capital of the
Company at a price of US$0.255 (~A$0.40) per share. The Company also agreed to
issue one free attaching option exercisable at US$0.32 (~A$0.50) with an
expiry date of 14 July 2026 for every two shares subscribed for under the
Placement.
Additionally, the Company conducted a second, strategic placement of
$US500,000. Under the Placement, the Company issued 1,480,000 fully paid
ordinary shares (Shares) at an issue price of AU$0.50 per Share, representing
nil discount to the 21 December 2023 closing price and approximately 5.5% to
the 5-day volume weighted average price (VWAP). The placement included one (1)
attaching option for every two (2) Placement Shares issued. The options are
exercisable at AU$1.00 each, with an expiry of 10 January 2027. The funds were
raised in order to support the Company's legal and marketing costs.
At the end of the December, the Company has ~A$6.482 million of cash on hand.
Accompanying this Activity Report is a Cash Flow Report for the Quarter ending
31 December 2023.
In accordance with ASX Listing Rule 4.7C.3 the Company advises that during the
December 2023 quarter, payments to related parties totalled A$276k, which
consisted of fees paid to executive and non-executive directors of the
Company.
As detailed in the accompanying Appendix 4C (Quarterly Cashflow Report),
cashflows during the quarter included A$238k cash outflows associated with
inventory production, A$733k for Research and development costs, ~A$2.3
million for administration costs (including product registration costs), and
cash inflows of ~A$12.1 million.
Results of Annual General Meeting
On 30 November 2023 the Company announced the voting results from the Annual
General Meeting of shareholders. The Company announced that all motions put to
the meeting were voted by poll, with all resolutions carried. Details of the
results can be found in the following URL:
https://www.investi.com.au/api/announcements/mxc/79f52b83-6ac.pdf
(https://www.investi.com.au/api/announcements/mxc/79f52b83-6ac.pdf)
Personnel Changes
On 1 December 2023 Dr Stephen Parker and Dr Ross Walker resigned as Directors
of the Company. Mr Daniel Robinson, with over 20 years' experience in a broad
range of corporate roles across stockbroking, corporate advisory, investor
relations and governance, was appointed in their place. The Company thanked Dr
Parker and Dr Walker for all their contributions to the Company over their
many years of service and wished them the very best for the next stage of
their careers.
CMC Markets UK PLC (CMC) were appointed as the Company's joint UK broker with
immediate effect on 1 December 2023. CMC is headquartered in London, with hubs
in Sydney and Singapore.
-ENDS-
Authorised for release by the board of directors, for further information
please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6555 2950 +61 8 6555 2950
info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk) info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe / Zach Cohen Aimee McCusker / Adam Pollock
+44 203 934 6630 +44 203 179 5300
mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk) aimeemccusker@oberoninvestments.com
(mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
(mailto:adampollock@oberoninvestments.com)
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European
pharmaceutical company with a strong commitment to creating accessible and
ethically produced cutting-edge medicines. Our approach combines in-house
research with innovative technologies, all aimed at discovering and producing
treatments for currently unmet medical conditions.
The company's founders and executives are distinguished figures in the global
pharmaceutical industry. Our central business strategy revolves around the
development and supply of innovative medicines, responding to the increasing
demand in the medical markets of Europe, North America, and Australasia.
MGC Pharma maintains a robust development pipeline that addresses two
prevalent medical conditions, with additional products currently in the
developmental stages. We've established strategic partnerships with renowned
institutions and academia, fostering the optimization of our medicines'
development. These medicines are produced in our EU-GMP Certified
manufacturing facilities, ensuring the highest quality standards.
With a growing patient base in key regions like the USA, UK, Australia, and
Ireland, MGC Pharma has also built a global distribution network through a
wide-reaching group of commercial partners. This extensive network places us
in a prime position to supply the global market effectively.
Follow us through our social media channels:
LinkedIn: MGC Pharmaceuticals Ltd.
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Instagram: @mgc_pharma
Forward Looking Statements
This announcement may include statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes", "estimates", "plans", "anticipates", "targets", "aims",
"continues", "expects", "intends", "hopes", "may, "will", "would", "could" or
"should" or, in each case, their negative or other variations or comparable
terminology. These forward-looking statements include matters that are not
facts. They include statements regarding the Directors' beliefs or current
expectations. By their nature, forward-looking statements involve risk and
uncertainty because they relate to future events and circumstances. Investors
should not place undue reliance on forward-looking statements, which speak
only as of the date of this announcement.
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
MGC PHARMACEUTICALS LTD
ABN Quarter ended ("current quarter")
30 116 800 269 31 December 2023
Consolidated statement of cash flows Current quarter $A'000 Year to date (6 months)
$A'000
1. Cash flows from operating activities
1.1 Receipts from customers 392 904
1.2 Payments for
(a) research and development (733) (830)
(b) product manufacturing and operating costs -
i) cost of sales / inventory (238) (523)
ii) operating costs (93) (93)
(c) advertising and marketing (496) (614)
(d) leased assets (75) (75)
(e) staff costs (2,340) (3,715)
(f) administration and corporate costs (including product (2,055) (3,070)
registrations)
1.3 Dividends received (see note 3) - -
1.4 Interest received - -
1.5 Interest and other costs of finance paid (23) (23)
1.6 Income taxes paid - -
1.7 Government grants and tax incentives 2 4
1.8 Other (GST/VAT refund) - -
1.9 Net cash from / (used in) operating activities (5,658) (8,036)
2. Cash flows from investing activities
2.1 Payments to acquire: - -
(a) entities - -
(b) businesses - -
(c) property, plant and equipment (3) (17)
(d) investments - -
(e) intellectual property - -
(f) other non-current assets - -
2.2 Proceeds from disposal of: - -
(a) entities
(b) businesses - -
(c) property, plant and equipment - -
(d) investments - -
(e) intellectual property - -
- -
(f) other non-current assets
2.3 Cash flows from loans to other entities - -
2.4 Dividends received (see note 3) - -
2.5 Other (cash acquired through assets acquisition) - -
2.6 Net cash from / (used in) investing activities (3) (17)
3. Cash flows from financing activities
3.1 Proceeds from issues of equity securities (excluding convertible debt 12,112 14,875
securities)
3.2 Proceeds from issue of convertible debt securities - -
3.3 Proceeds from exercise of options - -
3.4 Transaction costs related to issues of equity securities or convertible debt (385) (595)
securities
3.5 Proceeds from borrowings - -
3.6 Repayment of borrowings - -
3.7 Transaction costs related to loans and borrowings - -
3.8 Dividends paid - -
3.9 Other (loan entity which where control was gained after quarter-end) - -
3.10 Net cash from / (used in) financing activities 11,728 14,280
4. Net increase / (decrease) in cash and cash equivalents for the period Current quarter Year to date (6 months)
$A'000
$A'000
4.1 Cash and cash equivalents at beginning of period 417 240
4.2 Net cash from / (used in) operating activities (item 1.9 above) (5,658) (8,016)
4.3 Net cash from / (used in) investing activities (item 2.6 above) (3) (17)
4.4 Net cash from / (used in) financing activities (item 3.10 above) 11,728 14,280
4.5 Effect of movement in exchange rates on cash held (1) (5)
4.6 Cash and cash equivalents at end of quarter 6,482 6,482
5. Reconciliation of cash and cash equivalents Current quarter Previous quarter
at the end of the quarter (as shown in the consolidated statement of cash
$A'000
$A'000
flows) to the related items in the accounts
5.1 Bank balances 6,457 391
5.2 Call deposits 26 26
5.3 Bank overdrafts - -
5.4 Other (provide details) - -
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 6,482 417
6. Payments to related parties of the entity and their associates Current quarter
$A'000
6.1 Aggregate amount of payments to related parties and their associates included 276
in item 1
6.2 Aggregate amount of payments to related parties and their associates included -
in item 2
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity
report must include a description of, and an explanation for, such payments.
The payments in 6.1 are payments to directors of the company for their service
during the quarter.
7. Financing facilities available Total facility amount at quarter end Amount drawn at quarter end
Note: the term "facility' includes all forms of financing arrangements
$A'000
$A'000
available to the entity.
Add notes as necessary for an understanding of the sources of finance
available to the entity.
7.1 Loan facilities - -
7.2 Credit standby arrangements - -
7.3 Other (please specify) 14,600 6,948
7.4 Total financing facilities 14,600 6,948
7.5 Unused financing facilities available at quarter - 7,652
end
7.6 Include in the box below a description of each facility above, including the
lender, interest rate, maturity date and whether it is secured or unsecured.
If any additional financing facilities have been entered into or are proposed
to be entered into after quarter end, include a note providing details of
those facilities as well.
$14.6M Convertible note facility with Mercer Street Opportunity Fund LLC.
Refer to ASX announcement on 29 July 2022 for further information.
8. Estimated cash available for future operating activities $A'000
8.1 Net cash from / (used in) operating activities (Item 1.9) (5,658)
8.2 Cash and cash equivalents at quarter end (Item 4.6) 6,482
8.3 Unused finance facilities available at quarter end (Item 7.5) 7,652
8.4 Total available funding (Item 8.2 + Item 8.3) 14,134
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1) 2.5
Note: if the entity has reported positive net operating cash flows in
item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated
quarters of funding available must be included in item 8.5.
8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following
questions:
1. Does the entity expect that it will continue to have
the current level of net operating cash flows for the time being and, if not,
why not?
Answer: N/A
2. Has the entity taken any steps, or does it propose to
take any steps, to raise further cash to fund its operations and, if so, what
are those steps and how likely does it believe that they will be successful?
Answer: N/A
3. Does the entity expect to be able to continue its
operations and to meet its business objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2
and 8.6.3 above must be answered.
Compliance statement
1 This statement has been prepared in accordance with
accounting standards and policies which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters
disclosed.
31 January 2024
Date:
...................................................................................
[lodge
electronically without signature]
Authorised by:
...................................................................................
Roby Zomer - Managing Director
Notes
1. This quarterly cash flow report and the accompanying
activity report provide a basis for informing the market about the entity's
activities for the past quarter, how they have been financed and the effect
this has had on its cash position. An entity that wishes to disclose
additional information over and above the minimum required under the Listing
Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in
accordance with Australian Accounting Standards, the definitions in, and
provisions of, AASB 107: Statement of Cash Flows apply to this report. If this
quarterly cash flow report has been prepared in accordance with other
accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows
from operating activities or cash flows from investing activities, depending
on the accounting policy of the entity.
4. If this report has been authorised for release to the
market by your board of directors, you can insert here: "By the board". If it
has been authorised for release to the market by a committee of your board of
directors, you can insert here: "By the [name of board committee - eg Audit
and Risk Committee]". If it has been authorised for release to the market by a
disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the
market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council's
Corporate Governance Principles and Recommendations, the board should have
received a declaration from its CEO and CFO that, in their opinion, the
financial records of the entity have been properly maintained, that this
report complies with the appropriate accounting standards and gives a true and
fair view of the cash flows of the entity, and that their opinion has been
formed on the basis of a sound system of risk management and internal control
which is operating effectively.
1 (#_ftnref1) Refer to ASX announcement dated 15 December 2020.
2 (#_ftnref2) Refer to ASX announcement dated 14 July 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END UPDGRGDBXDXDGSB
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group